Institute of Radiotherapy and Nuclear Medicine (IRNUM), Peshawar, Pakistan.
Pakistan Institute of Engineering and Applied Sciences (PIEAS), 45650 Islamabad, Pakistan.
Phys Med. 2018 Mar;47:64-72. doi: 10.1016/j.ejmp.2018.02.015. Epub 2018 Feb 28.
Rheumatoid arthritis (RA) is a chronic inflammatory disease that can potentially damage the synovial joints. One of the effective treatment modality for RA is radiation synovectomy (RSV) where properly selected radionuclide is injected into the joint space, enabling controlled destruction of diseased synovial membrane via radiation exposure. Radiation dosimetry in RSV appears challenging due to the heterogeneous nature of synovial membrane, nonuniform distribution and leakage of radionuclide from the synovial cavity. This article reviews the dosimetric perspective pertaining to RSV. Specifically, characteristics of radionuclide for RSV and radiation dose to target and non-target (i.e., articular cartilage, bone, bloodstream, gonads, etc.) tissues of patient have been discussed. The personal dose H(0.07) to the hands of medical staff (i.e., radiochemist, therapist physician, nurse) may be considerably high due to handling of high specific activities (∼500 MBq/ml for Y-90); such doses are typically measured using thermoluminescence dosimeters (TLD) ring dosimeters and ranges from 1 to 21.5, 0.1 to 40 and 0.1 to 5 µSv/MBq for the radiochemist, therapist physician and the nurse, respectively. Methods to minimize radiation doses to the patient, medical staff and public are elaborated. Contamination risks and precautionary measures are also reported.
类风湿关节炎(RA)是一种慢性炎症性疾病,可能会损害滑膜关节。RA 的一种有效治疗方法是放射性滑膜切除术(RSV),将适当选择的放射性核素注入关节腔,通过辐射暴露来控制病变滑膜的破坏。由于滑膜膜的异质性、放射性核素从滑膜腔的不均匀分布和泄漏,RSV 中的辐射剂量测定似乎具有挑战性。本文综述了 RSV 的剂量学观点。具体而言,讨论了 RSV 用放射性核素的特性以及对患者的靶组织(即关节软骨、骨骼、血液、性腺等)和非靶组织(即关节软骨、骨骼、血液、性腺等)的辐射剂量。由于处理高比活度(对于 Y-90 约为 500 MBq/ml),医护人员(即放射化学家、治疗医师、护士)手部的个人剂量 H(0.07)可能相当高;此类剂量通常使用热释光剂量计(TLD)环剂量计进行测量,放射化学家、治疗医师和护士的剂量范围分别为 1 至 21.5、0.1 至 40 和 0.1 至 5 µSv/MBq。详细阐述了将患者、医护人员和公众的辐射剂量降至最低的方法。还报告了污染风险和预防措施。